AI-derived risk stratification tool that determines a probability of kidney transplant rejection for each patient.
Empower your practice with smarter insights from AlloSure Plus
Integrated
Offers a multimodal, unified view of rejection risk based on the integration of AlloSure and traditional tools, including eGFR, proteinuria, history of prior rejection, and kidney graft instability (change in creatinine).
Automated
Utilizes an AI-derived model to combine clinical data automatically pulled from the EMR*, reducing clinical burden and enabling timely intervention.
Available on Epic Aura and updated versions of Ottr and TransChart.
Clinically Validated
Independently validated in a robust international study published by Nature Medicine by the Paris Transplant Group.¹,²
* Available to Care Portal users without automation; manual input required.eGFR: estimated glomerular filtration rate; EMR: electronic medical record.
Clinically validated in over 2,700 biopsies in an international study¹,²
AlloSure Plus was evaluated in a large, international, multicenter observational study utilizing Banff 2022 Classification*.
* AlloSure Plus is referred to as integrative donor-derived cell-free DNA or “idd-cfDNA” in this study. AMR: antibody-mediated rejection; C4d: complement component 4d; DSA: donor-specific antibodies; eGFR: estimated glomerular filtration rate; TCMR: T cell-mediated rejection.
Increase accuracy in detecting rejection¹,²
AlloSure Plus provides superior accuracy over traditional tools or AlloSure alone.
Further risk stratify with AlloSure Plus probability of rejection results
Resources
Webinars
Events
Connect with our team to learn more about AlloSure Plus
Aubert O, et al. Nat Med. 2024;30(8):2320-2327 (assessing performance of AlloSure Plus with DSA).
Oral WTC presentation by Dr. Romain Brousse on August 5, 2025 (assessing performance of AlloSure Plus without DSA); CareDx data on file.